Retatrutide: Research Applications

Aplicacoes de Pesquisa

Retatrutide is under ativo(a) preclinical and clinical investigation across 7+ principal research domains, leveraging its unique triple-agonista do receptor mechanism:

1. Obesity and Weight Management — O(a) principal investigacional focus. Phase 2 trials (Jastreboff et al., 2023) demonstrated dose-dependente perda de peso up to 24.2% at 48 weeks com o(a) 12 mg dose, and perda de peso nao tinha plateaued at study conclusion.[1] Phase 3 TRIUMPH program data confirmou up to 28.7% mean perda de peso at 68 weeks (aproximadamente 71.2 lbs average), com o(a) 12 mg dose group showing the greatest reductions.[5] Estudos pre-clinicos in diet-induziu camundongos obesos demonstrated 36.9% peso corporal loss (vs. 21.2% for tirzepatide) with 86.8% massa gorda reduction.[4]
2. Type 2 Diabetes Mellitus (T2D) — Rosenstock et al. (2023) demonstrated significant glycemic improvements in Phase 2, with HbA1c reductions of up to -2.02% no(a) 12 mg dose over 36 weeks, along with improvements in fasting glucose, sensibilidade a insulina, and beta-cell function.[2] Body composition substudies confirmou que perda de peso was primariamente driven by massa gorda reduction.[6]
3. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD) — A Phase 2a substudy by Sanyal et al. (2024) publicado(a) em Nature Medicine demonstrated que the 8 mg and 12 mg doses normalized liver fat (<5%) in over 85% of participants, with relative liver fat reductions of up to 86% em relacao ao basal. Este efeito is linked to glucagon receptor-mediated aumenta in hepatico(a) fatty acid oxidation and elevated beta-hydroxybutyrate biomarcadors.[3]
4. Cardiovascular Disease (CVD) — The TRIUMPH-OUTCOMES Phase 3 trial is assessing se retatrutide reduz a incidencia of principal adverse eventos cardiovasculares (MACE) in adults with obesidade and estabeleceu atherosclerotic doenca cardiovascular. Pre-trial data show dose-dependente heart rate aumenta que peak at 24 weeks before declining.[5][10]
5. Chronic Kidney Disease (CKD) — The TRANSCEND-CKD trial is investigating retatrutide's effects on kidney structure and function, incluindo medido(a) glomerular filtration rate (mGFR). Post-hoc analyses from Phase 2 data suggested potential renoprotective effects, incluindo reduziu albuminuria and melhorou renal hemodynamics over time.[7][9]
6. Knee Osteoarthritis (OA) — The TRIUMPH-4 Phase 3 trial evaluates retatrutide in subjects with obesidade and knee osteoartrite. Results showed a significant reduction in WOMAC pain scores (up to 75.8% improvement) and melhorou physical function, alongside substantial perda de peso.[5]
7. Obstructive Sleep Apnea (OSA) — Included dentro do(a) TRIUMPH-1 and TRIUMPH-2 basket trials, research aims to determine retatrutide's efficacy in reducing the apnea-hypopnea index in subjects with obesidade.[5]
8. Obesity-Associated Cancer — Preclinical research by Marathe et al. (2025) demonstrated que retatrutide-induziu perda de peso reduziu tumor engraftment, retardou tumor onset, and significantly atenuou tumor growth in pancreatic and lung cancer models, outperforming semaglutide. Antitumor effects persisted apesar de partial weight regain, suggesting durable sistemico(a) and tumor immune reprogramming.[14]
9. Diabetic Kidney Disease (DKD) — Em estudos pre-clinicos, Ma et al. (2025) showed retatrutide demonstrated superior efficacy over liraglutide and tirzepatide in controlling risk factors associado(a) com diabetic doenca renal in db/db mice, effectively mitigating inflammatory and fibrotic processes.[15]

Clinical Efficacy Summary by Dose (Phase 2)

Dose	Weight Loss (48 wks, Obesity)	HbA1c Reduction (36 wks, T2D)	Evidence
1 mg	-8.7%	—	Jastreboff et al. (2023)[1]
0.5 mg	—	-0.43%	Rosenstock et al. (2023)[2]
4 mg	-17.1%	~-1.3%	[1][2]
8 mg	-22.8%	~-1.9%	[1][2]
12 mg	-24.2%	-2.02%	[1][2]